Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 6.9% – Should You Buy?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s stock price was up 6.9% during mid-day trading on Friday . The stock traded as high as $32.35 and last traded at $32.5070. Approximately 378,671 shares changed hands during trading, a decline of 46% from the average session volume of 700,505 shares. The stock had previously closed at $30.40.

Wall Street Analyst Weigh In

STOK has been the topic of a number of recent research reports. Weiss Ratings downgraded Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Wall Street Zen lowered Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Wedbush boosted their target price on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Finally, Canaccord Genuity Group lifted their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Trading Up 5.3%

The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -11.39 and a beta of 1.17. The company has a fifty day moving average of $31.51 and a two-hundred day moving average of $32.36.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The company had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. As a group, sell-side analysts predict that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 1,795 shares of Stoke Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the transaction, the insider owned 34,826 shares in the company, valued at $1,064,979.08. This trade represents a 4.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the sale, the general counsel owned 18,086 shares of the company’s stock, valued at $541,675.70. This trade represents a 7.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently added to or reduced their stakes in STOK. Kestra Advisory Services LLC bought a new position in Stoke Therapeutics in the 4th quarter worth approximately $26,000. KBC Group NV bought a new stake in shares of Stoke Therapeutics in the first quarter valued at approximately $36,000. Harbour Investments Inc. boosted its position in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after acquiring an additional 898 shares during the period. Western Wealth Management LLC acquired a new stake in shares of Stoke Therapeutics in the first quarter worth $55,000. Finally, Generali Investments Management Co LLC acquired a new stake in shares of Stoke Therapeutics in the third quarter worth $41,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.